Global Parkinson’s Disease Drugs Market Overview:
According to SPER Market Research, the Global Parkinson’s Disease Drugs Market is estimated to reach USD 10.93 billion by 2032 with a CAGR of 6.5%.
Parkinson's Disease, also known as idiopathic Parkinsonism, is a neurodegenerative disease. It is a progressive disease that affects both the neurological system and the bodily components controlled by the nervous system. Dopamine is produced in the substantia nigra region of the brain. Dopamine levels decrease in Parkinson's Disease as substantial cells in the brain begin to die. Parkinson's Disease may be caused by environmental or genetic factors. Those with an affected family member are at a higher risk of contracting the disease, as certain genes are known to be inheritable risk factors. Tremors, slowed movement, rigid muscles, impaired posture and balance, speech changes, and other symptoms are common. Non-motor symptoms usually appear gradually, and as the disease progresses, they become more common. Age is the most important risk factor, but other factors such as environment and heredity also play a role.
Significant factors driving market growth include a large patient pool and an increasing rate of diagnosis. According to the Parkinson's Disease Foundation, nearly 10 million people worldwide suffer from this disorder. This disorder is most common in developed countries, with nearly 60,000 new cases reported each year in the United States. Demand for Parkinson's Disease drugs is expected to rise globally during the forecast period, owing to an increase in the geriatric population, which drives the market growth. Furthermore, increases in R&D investments by key players in Parkinson’s Disease drugs, as well as an increase in the geriatric population, are some factors driving the growth of the Parkinson's Disease drugs industry. The COMT inhibitors are expected to grow at the fastest rate during the forecast period due to advantages such as long-lasting enzyme inhibition, reduced adverse effects of drugs, and lower levodopa dose. The oral route of administration is expected to grow the fastest during the forecast period, owing to more pre-determined doses, convenience, and patient self-administration. The over-50 age group is expected to continue this trend during the forecast period. This is due to an aging population, as age is a risk factor for Parkinson's Disease, which increases the over-50 age group. However, the side effects of Parkinson's Disease drugs may limit the market growth.
Impact of COVID-19 on the Global Parkinson’s Disease Drugs Market
The global Parkinson's Disease drugs market fell in 2020 as a result of the global economic recession caused by COVID-19. However, the market will recover in the forecast period as a result of increased Parkinson's Disease drug adoption and an increase in Parkinson's Disease drug R&D pipeline products.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2032 |
| Base year considered | 2021 |
| Forecast period | 2022-2032 |
| Segments covered | By Age group, By Drug Class, By Route of administration |
| Geographies covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Companies Covered | AbbVie Inc., Amneal Pharmaceuticals, Inc., Biogen Inc., C.H., Boehringer Sohn Ko. KG, Eli Lilly and Company, F.Hoffmann-La Roche Ltd., Gentech Healthcare, GlaxoSmithKline Plc, Intas Pharmaceuticals Limited, Merck & Co., Inc., Novartis AG, Orion Corporation, Pfizer Inc., Square group, Sun Pharmaceutical Industries, Teva Pharmaceuticals, Torrent Group, UCB, Viatris Inc.
|
Global Parkinson’s Disease Drugs Market Segmentation:
By Age Group: Based on the Age Group, Global Parkinson’s Disease Drugs Market is segmented as; 50 or below 50 (Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region), Above 50 years (Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region).
By Drug Class: Based on the Drug Class, Global Parkinson’s Disease Drugs Market is segmented as; Decarboxylase Inhibitors {Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region, Decarboxylase Inhibitors Parkinson's Disease Drugs Market by Distribution Channel (Hospital Pharmacies Market size and forecast, by region, Drug stores and Retail Pharmacies Market size and forecast, by region, Online Providers Market size and forecast, by region), Dopamine Agonists (Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region), COMT Inhibitors (Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region), MAO-B Inhibitors (Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region), Others.
By Route of Administration:
Based on the ROA, Global Parkinson’s Disease Drugs Market is segmented as; Injectable (Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region), Oral (Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region), Transdermal (Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region).
By Region: During the forecast period, North America is expected to dominate the Parkinson's Disease drugs market, accounting for the largest share. This is due to factors such as the presence of key players in the region and the availability of diagnostic laboratories. Furthermore, high-quality healthcare in the United States is expected to drive the growth of the North American market.
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Global Parkinson’s Disease Drugs Market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. Global Parkinson’s Disease Drugs Market, By Age Group, 2019-2032 (USD Million)
6.1. 50 or below 50
6.1.1. Key market trends, growth factors and opportunities
6.1.2. Market size and forecast
6.1.3. Market analysis by Region
6.2. Above 50 years
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast
6.2.3. Market analysis by Region
7. Global Parkinson’s Disease Drugs Market, By Drug Class, 2019-2032 (USD Million)
7.1. Decarboxylase Inhibitors
7.1.1. Key market trends, growth factors and opportunities
7.1.2. Market size and forecast
7.1.3. Market analysis by Region
7.1.4. Decarboxylase Inhibitors Parkinson's Disease Drugs Market by Distribution Channel
7.1.4.1 Hospital Pharmacies Market size and forecast, by region
7.1.4.2 Drug stores and Retail Pharmacies Market size and forecast, by region
7.1.4.3 Online Providers Market size and forecast, by region
7.2. Dopamine Agonists
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast
7.2.3. Market analysis by Region
7.3. COMT Inhibitors
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast
7.3.3. Market analysis by Region
7.4. MAO-B Inhibitors
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast
7.4.3. Market analysis by Region
7.5. Others
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast
7.5.3. Market analysis by Region
8. Global Parkinson’s Disease Drugs Market, By Route of Administration, 2019-2032 (USD Million)
8.1. Injectable
8.1.1. Key market trends, growth factors and opportunities
8.1.2. Market size and forecast
8.1.3. Market analysis by Region
8.2. Oral
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast
8.2.3. Market analysis by Region
8.3. Transdermal
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast
8.3.3. Market analysis by Region
9. Global Parkinson’s Disease Drugs Market, By Region, 2019-2032 (USD Million)
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia-Pacific
9.4. South America
9.4.1. Brazil
9.4.2. Argentina
9.4.3. Rest of South America
9.5. Middle East & Africa
9.5.1. Kingdom of Saudi Arabia
9.5.2. United Arab Emirates
9.5.3. Rest of Middle East & Africa
10. Company Profiles
10.1. AbbVie Inc.
10.1.1. Company details
10.1.2. Financial outlook
10.1.3. Product summary
10.1.4. Recent developments
10.2. Amneal Pharmaceuticals, Inc.
10.2.1. Company details
10.2.2. Financial outlook
10.2.3. Product summary
10.2.4. Recent developments
10.3. Biogen Inc., C.H.
10.3.1. Company details
10.3.2. Financial outlook
10.3.3. Product summary
10.3.4. Recent developments
10.4. Boehringer Sohn Ko. KG
10.4.1. Company details
10.4.2. Financial outlook
10.4.3. Product summary
10.4.4. Recent developments
10.5. Eli Lilly and Company
10.5.1. Company details
10.5.2. Financial outlook
10.5.3. Product summary
10.5.4 Recent developments
10.6. F.Hoffmann-La Roche Ltd.
10.6.1. Company details
10.6.2. Financial outlook
10.6.3. Product summary
10.6.4. Recent developments
10.7. Gentech Healthcare
10.7.1. Company details
10.7.2. Financial outlook
10.7.3. Product summary
10.7.4. Recent developments
10.8. GlaxoSmithKline Plc
10.8.1. Company details
10.8.2. Financial outlook
10.8.3. Product summary
10.8.4. Recent developments
10.9. Intas Pharmaceuticals Limited
10.9.1. Company details
10.9.2. Financial outlook
10.9.3. Product summary
10.9.4. Recent developments
10.10. Merck & Co., Inc.
10.10.1. Company details
10.10.2. Financial outlook
10.10.3. Product summary
10.10.4. Recent developments
10.11 Novartis AG
10.11.1. Company details
10.11.2. Financial outlook
10.11.3. Product summary
10.11.4. Recent developments
10.12. Orion Corporation
10.12.1. Company details
10.12.2. Financial outlook
10.12.3. Product summary
10.12.4. Recent developments
10.13. Pfizer Inc.
10.13.1. Company details
10.13.2. Financial outlook
10.13.3. Product summary
10.13.4. Recent developments
10.14. Square group
10.14.1. Company detail
10.14.2. Financial outlook
10.14.3. Product summary
10.14.4. Recent developments
10.15. Sun Pharmaceutical Industries
10.15.1. Company details
10.15.2. Financial outlook
10.15.3. Product summary
10.15.4. Recent developments
10.16. Teva Pharmaceuticals
10.16.1. Company details
10.16.2. Financial outlook
10.16.3. Product summary
10.16.4. Recent development
10.17. Torrent Group
10.17.1. Company details
10.17.2. Financial outlook
10.17.3. Product summary
10.17.4. Recent development
10.18. UCB
10.18.1. Company details
10.18.2. Financial outlook
10.18.3. Product summary
10.18.4. Recent development
10.19. Viatris Inc.
10.19.1. Company details
10.19.2. Financial outlook
10.19.3. Product summary
10.19.4. Recent development